Vertex Pharmaceuticals, Inc. (VRTX) Posts Smaller Q2 Loss
Get Alerts VRTX Hot Sheet
EPS Growth %: +32.1%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
DSGN, ATRA, CRVS, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q2 EPS of ($0.61), $0.10 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $138 million versus the consensus estimate of $131.85 million. Revenues was $113 million from KALYDECO.
"As we enter the second half of the year, we continue to make significant progress toward achieving all of our key goals," commented Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "Based on data generated throughout the first half of this year, we have increased confidence in our scientific approach to treating the underlying cause of CF and believe that we are on the right path to help the vast majority of people with this disease in the coming years. Importantly, with a strong financial platform, we are today well positioned to invest in our business to create future medicines and grow our revenues as we advance toward profitability."
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Eyenovia Inc (EYEN) Misses Q4 EPS by 1c
- Motus GI Holdings (MOTS) Tops Q4 EPS by 130c
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!